Abstract: The present disclosure relates to amyloid beta (A?) channels and the diseases and disorders caused by abnormal activity in these channels, such as Alzheimer's disease, Lewy body dementia, inclusion body myositis, or cerebral amyloid angiopathy. The disclosure provides compositions and methods that block AO channel activity and/or reduce A?-induced toxicity in a cell. Compositions comprised of compounds having histidine coordinating capacity are used in methods to prevent, reduce, or eliminate damage caused by A? ion channels.
Type:
Application
Filed:
March 18, 2009
Publication date:
January 20, 2011
Applicant:
he Henry M. JAckson Foundation for the Advancement of Military Medicine, Inc.
Abstract: The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum circumsporozoite protein (CSP) operably linked to a human CMV promoter, and/or (b) a second adenoviral vector comprising a nucleic acid sequence encoding a P. falciparum apical membrane antigen 1 (AMA-1) antigen operably linked to a human CMV promoter.
Type:
Application
Filed:
January 9, 2008
Publication date:
November 4, 2010
Applicant:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Joseph T. Bruder, C. Richter King, Thomas Richie, Keith Limbach, Denise Louise Doolan
Abstract: A scrub typhus diagnostic method and vaccine using a composition comprising truncated r47 protein and truncated r56 protein is disclosed. Vaccines composed of r56 protein variants are also disclosed. Methods of reducing HIV viral loads using r47 and r56 proteins and antibodies raised against r47 and r56 are also disclosed.
Type:
Grant
Filed:
October 23, 2007
Date of Patent:
October 26, 2010
Assignees:
The United States of America as represented by the Secretary of the Navy, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Wei Mei Ching, Hong Ge, Chien-Chung Chao
Abstract: A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.
Type:
Grant
Filed:
July 2, 2008
Date of Patent:
October 5, 2010
Assignee:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Inventors:
Shiv Srivastava, Judd W. Moul, Vasantha Srikantan, Zhiqiang Zou
Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.
Type:
Application
Filed:
October 2, 2009
Publication date:
September 30, 2010
Applicants:
HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, ALTOR BIOSCIENCE CORPORATION
Inventors:
GERALD WALTER FISCHER, RICHARD F. SCHUMAN, HING WONG, JEFFREY R. STINSON
Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
Type:
Application
Filed:
December 23, 2008
Publication date:
September 2, 2010
Applicants:
Henry M. Jackson Foundation for the Advancement of Military Medicine, Altor BioScience Corporation
Inventors:
Gerald W. Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
Abstract: Methods for improving spatial and/or temporal resolution of digital images and for improving image data transmission by a novel technique—back pixelation, which involves data processing and reconstruction of overlaid images from multiple acquisition or multiple sampling. The back pixelation technique may be used for image data acquisition and transmission; it may be applied prospectively or retrospectively. In particular, the methods of this invention may be used in reducing the pixel size of a two-dimensional image or the voxel size of a three dimensional image; producing a two- or three-dimensional image from a multiplicity of images acquired from an object which are capable of overlaying one another by an increment; producing and transmitting a two- or three-dimensional image by multiple acquisitions according to an acquisition matrix; or transmitting a two- or three-dimensional image by reducing or decomposing the image to a plurality of image data packets and transmitting the same.
Type:
Grant
Filed:
October 9, 2003
Date of Patent:
August 17, 2010
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Abstract: Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2X7 protein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2X7 in cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2X7 in cells are described.
Type:
Grant
Filed:
June 2, 2006
Date of Patent:
August 3, 2010
Assignees:
University Hopitals of Cleveland, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
George Gorodeski, Ying-Hong Feng, Xin Li
Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.
Type:
Application
Filed:
August 6, 2009
Publication date:
July 29, 2010
Applicants:
Henry M. Jackson Foundation for the Advancement of Military Medicine, Sunol Molecular Corporation
Inventors:
Jeffrey R. Stinson, Hing Wong, Alison D. O'Brien, Clare K. Schmitt, Angela Melton-Celsa
Abstract: A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.
Type:
Application
Filed:
July 2, 2008
Publication date:
July 22, 2010
Applicant:
The Henry M. Jackson Foundation for the Advancement of Military Medicine
Inventors:
Shiv Srivastava, Vasantha Srikantan, Zhiqiang Zou, Judd W. Moul
Abstract: A method of treating spinal cord injury (SCI) includes transcutaneously irradiating at least a portion of a spinal environment of the patient with light having a power density of at least about 0.01 mW/cm2 at the portion of the spinal environment.
Type:
Grant
Filed:
January 7, 2008
Date of Patent:
April 13, 2010
Assignees:
The United States of America as represented by the Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military Medicine
Inventors:
Juanita J. Anders, Ilko K. Ilev, Ronald W. Waynant, Kimberly R. Byrnes
Abstract: Fusion of the membrane of enveloped viruses with the plasma membrane of a receptive host cell is a prerequisite for viral entry and infection and an essential step in the life cycle of all enveloped viruses, such as paramyxoviruses. The instant invention is directed to providing polypeptides which are a heptad portion of a Henipavirus F protein effective against fusion between a membrane of a paramyxovirus and a plasma membrane of a cell. The instant invention also provides nucleic acids, compositions, and methods effective against paramyxovirus infection. Accordingly, the instant invention provides therapeutic agents and vaccines effective against paramyxoviruses viruses, especially HeV or NiV.
Type:
Grant
Filed:
November 13, 2002
Date of Patent:
February 23, 2010
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Christopher C. Broder, Katharine N. Bossart
Abstract: The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.
Type:
Grant
Filed:
June 23, 2006
Date of Patent:
October 27, 2009
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by energy, as in unresponsiveness.
Type:
Grant
Filed:
March 8, 2002
Date of Patent:
June 16, 2009
Assignees:
Board of Regents, The University of Texas System, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Constantin G. Ioannides, George E. Peoples, Jr.
Abstract: This invention relates to the androgen-regulated gene, PMEPA1, and proteins encoded by this gene, including variants and analogs thereof. Also provided are other androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer.
Type:
Grant
Filed:
June 15, 2006
Date of Patent:
May 26, 2009
Assignee:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Inventors:
Shiv Srivastava, Judd W. Moul, Linda L. Xu
Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
Type:
Grant
Filed:
August 1, 2005
Date of Patent:
March 31, 2009
Assignees:
Henry M. Jackson Foundation for the Advancement of Military Medicine, Altor BioScience Corporation
Inventors:
Gerald Walter Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
Abstract: This invention provides methods, including a method of assessing the prognosis of a breast cancer patient, comprising assaying for loss of heterozygosity at the 10q21 region of the genome of the patient, a method of identifying a probability that a patient with breast cancer has metastasized breast cancer, a method of determining a survival probability of a patient with breast cancer, and a method of identifying a probability that a patient with prostate cancer has a severe form of prostate cancer. This invention also provides assay complexes, including assay complexes which comprise at least one prostate tissue sample or tissue sample extract, an antibody that specifically binds ANX7, and a label, or which comprise at least one breast tissue sample or tissue sample extract, an antibody that specifically binds ANX7, and a label.
Type:
Grant
Filed:
December 22, 2004
Date of Patent:
March 17, 2009
Assignee:
Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: The present invention relates to the elucidation of the role of erythropoietin and the erythropoietin receptor in the development and progression of certain solid tumors, including those found in breast, cervical, uterine, ovarian, prostate and brain cancer.
Type:
Grant
Filed:
November 30, 2001
Date of Patent:
October 7, 2008
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
Type:
Grant
Filed:
September 28, 2005
Date of Patent:
December 4, 2007
Assignees:
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of the Army
Inventors:
Bernard Moss, Patricia L. Earl, Linda Wyatt, Leigh Anne Eller, Thomas C. VanCott, Matthew Edward Harris
Abstract: The invention describes the identification, making, and isolation of immunoglobulin and antigen useful for preventing, diagnosing, and treating staphylococcal infections. The invention further describes an in vivo animal model useful for testing the efficacy of pharmaceutical compositions, including pharmaceutical compositions of immunoglobulin and isolated antigen.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
October 9, 2007
Assignee:
Henry M. Jackson Foundation for the Advancement of Military Medicine